Abstract:Neuropathic pain, a debilitating condition, remains challenging to manage effectively. An insight into neuropharmacological mechanisms is critical for optimizing treatment strategies. This systematic review aims to evaluate the role of neuropharmacological agents based on their efficacy, involved neurotransmitters, and receptors. A manual literature search was undertaken in PubMed including Medline, Cochrane Library, Google Scholar, Plos One, Science Direct, and clinicaltrials.gov from 2013 until 2023. Out of the 13 included studies, seven evaluated the role of gabapentinoids. Two main drugs from this group, gabapentin and pregabalin, function by binding voltage-gated calcium channels, lowering neuronal hyperexcitability and pain signal transmission, thereby relieving neuropathic pain. Four of the pooled studies reported the use of tricyclic antidepressants (TCAs) including amitriptyline and nortriptyline which work by blocking the reuptake of norepinephrine and serotonin, their increased concentration is thought to be central to their analgesic effect. Three articles assessed the use of serotonin-norepinephrine reuptake inhibitors (SNRIs) and reported them as effective as the TCAs in managing neuropathic pain. They work by augmenting serotonin and norepinephrine. Three studies focused on the use of selective serotonin reuptake inhibitors (SSRIs), modulating their effect by increasing serotonin levels; however, they were reported as not a highly effective treatment option for neuropathic pain. One of the studies outlined the use of cannabinoids for neuropathic pain by binding to cannabinoid receptors with only mild adverse effects. It is concluded that gabapentinoids, TCAs, and SNRIs were reported as the most effective therapy for neuropathic pain; however, for trigeminal neuralgia, anticonvulsants like carbamazepine were considered the most effective. Opioids were considered second-line drugs for neuropathic pain as they come with adverse effects and a risk of dependence. Ongoing research is exploring novel drugs like ion channels and agents modulating pain pathways for neuropathic pain management. Our review hopes to inspire further research into patient stratification by their physiology, aiding quicker and more accurate management of neuropathic pain while minimizing inadvertent side effects.

Pharmacotherapy and noninvasive neurostimulation for neuropathic pain

Non-invasive Brain Stimulation Interventions for Management of Chronic Central Neuropathic Pain: a Scoping Review Protocol

Advances in the interventional management of neuropathic pain

Pharmacologic and Nonpharmacologic Management of Neuropathic Pain

Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies

Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls

[Therapeutic advances in pharmaceutical treatment of neuropathic pain]

Neuromodulation for Neuropathic Pain Syndromes

Neuropharmacology of Neuropathic Pain: A Systematic Review

Non-Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review

Interventional Therapy for Neuropathic Pain

Potential Novel Therapeutic Strategies for Neuropathic Pain

Neuropathic pain: Evidence based recommendations

Progress in Treatment of Pathological Neuropathic Pain after Spinal Cord Injury

EFNS guidelines on neurostimulation therapy for neuropathic pain

An overview of the non‐procedural treatment options for peripheral neuropathic pain

Advancements in Modern Treatment Approaches for Central Post-Stroke Pain: A Narrative Review

Targeting sensory neuron GPCRs for peripheral neuropathic pain

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

Research progress of mechanisms and drug therapy for neuropathic pain

Treating neuropathic pain and comorbid affective disorders: Preclinical and clinical evidence